PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Protalix BioTherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.56−0.06 (-2.29%)
Close on Oct 19, 2026
- Market cap
- $211.35M
- P/E (TTM)
- 11.1
- Dividend yield
- –
Dividends
Protalix BioTherapeutics has not reported a dividend
No dividend per share appears in Protalix BioTherapeutics's annual filings since fiscal 2010.